An interventional study of Investigational cream in Atopic Dermatitis and Psoriasis, sponsored by Brainfarma Industria Química e Farmacêutica S/A. Not yet recruiting at 1 site in Brazil. Open to participants aged 3 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Brainfarma Industria Química e Farmacêutica S/A (part of Hypera Pharma) · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to evaluate the cosmetic efficacy and safety of an investigational cream in participants with atopic dermatitis or psoriasis. The main questions it aims to answer are:
Does the investigational cream improve skin condition and participant-reported outcomes after 30 and 45 days of use? Does the investigational cream improve clinical signs, skin hydration, skin barrier function, skin pH, and quality of life in participants with atopic dermatitis or psoriasis?
Participants will:
Apply the investigational cream twice daily for 45 days. Attend study visits at baseline, Day 30, and Day 45. Undergo clinical, instrumental, and subjective assessments. Complete questionnaires regarding quality of life and product perception. Undergo skin hydration, transepidermal water loss, and skin pH evaluations.
1,591 studies on the registry are indexed under Dermatitis, Atopic; 286 are open to participants now.
This study's planned enrollment of 42 is below the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Brainfarma Industria Química e Farmacêutica S/A is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with atopic dermatitis will apply the investigational cream to the affected areas twice daily for 45 days.
Other: Investigational cream
Participants with psoriasis will apply the investigational cream to the affected skin areas on the face and/or body twice daily for 45 days.
Other: Investigational cream
Investigational cream intended for topical application to improve skin condition in individuals with atopic dermatitis or psoriasis. The cream is applied to affected skin areas twice daily for 45 days.
Also known as: Hydraporin AI Creme
Participant-perceived efficacy of the investigational cream after 30 and 45 days of use
Assessment of participants' perception of the efficacy of the investigational cream using a participant-reported questionnaire evaluating skin symptoms, with responses rated on a 4-point scale ranging from 0 (not relevant) to 3 (very much), after 30 and 45 days of continuous use.
Time frame: Day 30 and Day 45
Eczema Area and Severity Index (EASI) or Psoriasis Area and Severity Index (PASI) score after 30 and 45 days of use
Assessment of clinical disease severity using the Eczema Area and Severity Index (EASI) in participants with atopic dermatitis and the Psoriasis Area and Severity Index (PASI) in participants with psoriasis. For both scales, lower scores indicate less severe disease and higher scores indicate greater disease severity.
Time frame: Day 30 and Day 45
Skin hydration measured by Corneometer® after 30 and 45 days of use
Assessment of skin hydration in lesional and non-lesional skin using Corneometer® measurements. Higher values indicate greater skin hydration.
Time frame: Day 30 and Day 45
Transepidermal water loss measured by Tewameter®
Assessment of skin barrier integrity in lesional and non-lesional skin using transepidermal water loss measurements obtained with Tewameter®. Lower values indicate better skin barrier function.
Time frame: Day 30 and Day 45
Skin pH measured by pHmeter® after 30 and 45 days of useDay 45
Assessment of skin surface pH in lesional and non-lesional skin using pHmeter® measurements.
Time frame: Day 30 and Day 45
Dermatology Life Quality Index (DLQI) score after 30 and 45 days of use
Assessment of quality of life using the Dermatology Life Quality Index (DLQI). Total scores range from 0 to 30, with higher scores indicating greater impairment of quality of life.
Time frame: Day 30 and Day 45
Clinical improvement of target lesions assessed by standardized photography after 30 and 45 days of use
Assessment of clinical changes in target lesions through standardized photographic documentation.
Time frame: Day 30 and Day 45
Use of topical corticosteroid rescue medication during the study period
Assessment of the need for topical corticosteroid rescue medication during treatment with the investigational cream.
Time frame: Baseline through Day 45
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
Of 69 industry-sponsored interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 4 months is below that.
Counting every sponsor, half of 182 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brainfarma Industria Química e Farmacêutica S/A →